drugset / Trial / NCT02495623

A Study of the Effect of SYN-010 on Subjects With IBS-C

NCT02495623 ↗

Phase 2 Completed 63 enrolled Theriva Biologics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with Irritable Bowel Syndrome with Constipation (IBS-C)

Timeline

Start
2015-06
Primary completion
2015-10
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator SYN-010 Unknown 21 mg —
Comparator SYN-010 Unknown 42 mg —